Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals (XENE) is a clinical-stage biopharmaceutical company pioneering neuroscience therapies through its innovative extreme genetics platform. This page serves as the definitive source for verified company news, providing investors and researchers with timely updates on therapeutic advancements and strategic developments.
Access curated press releases covering clinical trial milestones, regulatory updates, and research collaborations. Our news collection focuses on XENE's work identifying novel drug targets through genetic analysis of severe disorders, particularly in neurology and psychiatry. Track progress across their pipeline of precision therapies targeting ion channels and neurological pathways.
Key updates include phase trial results, patent filings, executive appointments, and scientific presentations. All content is vetted for accuracy and relevance to investment research. Bookmark this page for efficient monitoring of XENE's progress in genetic-driven drug discovery and partnership announcements within the neuroscience sector.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) held its Annual Meeting on June 3, 2021, announcing a leadership transition with Ian Mortimer as the new CEO and Sherry Aulin as CFO. Dr. Simon Pimstone transitions to Executive Chair, recognizing the contributions of long-serving board members. Elizabeth Garofalo was elected to the board, bringing extensive experience in neurology. The company focuses on developing therapies for neurological disorders, emphasizing its pipeline targeting unmet medical needs in epilepsy.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will present at the Jefferies 2021 Virtual Healthcare Conference on June 2, 2021, at 3:00 PM ET. The event will feature a fireside chat accessible via a live webcast. This participation highlights Xenon's commitment to advancing its pipeline of innovative therapeutics for neurological disorders, particularly focusing on epilepsy. Interested investors can find more information on the company's presentations and webcasts on their investor website. Note that the schedule is subject to change.
Xenon Pharmaceuticals reported Q1 2021 financial results, highlighting a net loss of $15.8 million, compared to $7.5 million in Q1 2020. Total revenue for the quarter was $4.4 million, down from $7.1 million year-over-year. The company completed patient screening in the Phase 2b ‘X-TOLE’ clinical trial for XEN1101 and anticipates topline data by Q3 2021. Following a public offering, Xenon bolstered its cash reserves to $274.7 million, sufficient to fund operations into 2023. The company also aims to advance multiple clinical trials targeting neurological disorders, including major depressive disorder.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will disclose its first quarter 2021 financial results on May 11, 2021, after U.S. market close. A live conference call is scheduled for 4:30 PM ET, accessible via phone or through Xenon’s investor website. The company focuses on developing innovative neurology therapies, particularly for epilepsy, with a portfolio aimed at addressing significant medical needs.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced its participation in two upcoming virtual investor conferences. The first is the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 10:15 am ET, accessible via a live webcast. The second is the 2021 Bloom Burton & Co. Healthcare Investor Conference on April 20, 2021, at 3:00 pm ET, also available through a live webcast. The company focuses on developing innovative therapeutics for neurological disorders, particularly epilepsy. More information can be found on their investor website.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced its participation in a virtual fireside chat at the Stifel 3rd Annual CNS Day on March 31, 2021, at 1:00 pm ET. The discussion will focus on the company’s innovative therapies for neurological disorders, particularly epilepsy. Investors can access the live webcast on the company's website, where it will also be archived for future viewing. The presentation times are subject to change, emphasizing the need for stakeholders to stay updated.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) has successfully closed an underwritten public offering of 5,135,135 common shares, including an additional 810,810 shares from the underwriters' exercised option. The shares were priced at $18.50 each, while pre-funded warrants to purchase 1,081,081 common shares were offered at $18.4999. The total gross proceeds from the offering are approximately $115.0 million, before deductions. Jefferies, Stifel, and William Blair acted as joint book-running managers for the offering.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced a public offering of 4,324,325 common shares priced at $18.50 each, alongside pre-funded warrants for 1,081,081 common shares at $18.4999. The offering aims to raise approximately $100 million before deductions. An additional option for underwriters to purchase 810,810 shares exists for 30 days. The offering is anticipated to close around March 12, 2021, subject to standard conditions. Jefferies, Stifel, and William Blair are leading the offering, with further details available through their channels.
Xenon Pharmaceuticals (Nasdaq:XENE) has initiated an underwritten public offering of its common shares, including pre-funded warrants for select investors. The offering is made under its existing shelf registration statement, with underwriters given a 30-day option to purchase an additional 15% of the shares offered. The transaction, led by Jefferies, Stifel, and William Blair, is subject to market conditions and may not be completed as anticipated. No shares will be sold in Canada, and a preliminary prospectus will be filed with the SEC.
Xenon Pharmaceuticals has announced the acceptance of its Investigational New Drug (IND) application by the U.S. FDA and IRB approval for a Phase 2 clinical trial of XEN1101, aimed at treating major depressive disorder (MDD) and anhedonia. The trial will be conducted in collaboration with the Icahn School of Medicine at Mount Sinai, with Dr. James W. Murrough as the principal investigator. This study will evaluate the antidepressant effects of XEN1101, utilizing a randomized, double-blind, placebo-controlled design involving approximately 60 patients, expected to start in Q2 2021.
FAQ
What is the current stock price of Xenon Pharmaceut (XENE)?
What is the market cap of Xenon Pharmaceut (XENE)?
